US20010049138A1 - Method for chemically acellularizing a biological tissue sample - Google Patents
Method for chemically acellularizing a biological tissue sample Download PDFInfo
- Publication number
- US20010049138A1 US20010049138A1 US09/896,651 US89665101A US2001049138A1 US 20010049138 A1 US20010049138 A1 US 20010049138A1 US 89665101 A US89665101 A US 89665101A US 2001049138 A1 US2001049138 A1 US 2001049138A1
- Authority
- US
- United States
- Prior art keywords
- solution
- tissue sample
- nerve
- detergent
- acellularized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/52—Fibronectin; Laminin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- C12N2533/92—Amnion; Decellularised dermis or mucosa
Definitions
- This invention relates to the field of tissue engineering, and more particularly to a method for chemically acellularizing a biological tissue sample, such as a peripheral nerve.
- Peripheral nerve injuries are exceedingly common, occurring clinically after injury or surgical resection.
- the resulting nerve gaps can produce significant disability and thus require surgical repair.
- Primary end-to-end nerve coaptation is the procedure of choice for peripheral nerve reconstruction, but in many circumstances the gap between the proximal and distal stump is too large to allow for a tension-free repair. Under these circumstances, surgeons must employ alternate repair techniques, such as nerve grafting.
- Peripheral nerve autografts are the gold standard for nerve grafting procedures and provide the optimal degree of reinnervation when primary end-to-end neurorrhaphy is not an option.
- the functional deficits at the donor site following nerve graft harvest as well as the limited amounts of donor nerve tissue available restrict the use of autografts in many clinical situations.
- TLN termino-lateral neurorrhaphy
- TLN autogenous vein and plastic chamber conduits
- TLN entails suturing the distal stump of a severed nerve to the side of an intact adjacent nerve which is not always available.
- Autogenous vein grafts and plastic chambers are a plentiful supply of nerve regeneration conduits, yet neither provides the trophic support (nerve growth factor, etc.) necessary for axonal regeneration across nerve gaps greater than 2 cm, leading to poor functional outcomes.
- Peripheral nerve allografts provide another alternative for nerve repair. Although allografts overcome the problems associated with the previously mentioned repair methods, nerve allograft rejection becomes a major obstacle. Until long term tolerance to nerve allografts can be induced, this technique requires long term systemic immunosuppression and as a result has limited clinical applications.
- Acellular nerve grafts produced by a variety of techniques, have emerged as a possible alternative to overcome the immunogenicity of allografts.
- Previous attempts to create acellular nerve tissue have involved several methods, namely irradiation, fixation, heat treatment, or freezing, prior to grafting in an effort to kill or remove the cellular elements of the nerve allograft and reduce immunogenicity.
- Peripheral nerve grafts that have been acellularized by such methods have been shown to support axonal regeneration across short distances and to elicit a reduced immune response compared with standard peripheral nerve allografts.
- acellularization methods cause disruption of the cellular elements of the nerve and may concurrently disrupt the endoneurial tubes, thus reducing the potential for axonal elongation through the nerve graft.
- cellular debris remaining after the mechanical disruption process may also elicit an immune response which can adversely affect Schwann cell migration and axonal elongation.
- a method for chemically acellularizing a biological tissue sample such as a peripheral nerve.
- the method includes disrupting the cell membranes of the biological tissue sample, and then denaturing intracellular proteins within the cells of the tissue sample and removing the denatured proteins from the cells while preserving the extracellular matrix to produce an acellularized tissue construct without using mechanical agents.
- the tissue sample is harvested from a suitable donor, and then submersed in a balanced salt solution, such as Dulbecco's phosphate buffered saline.
- a balanced salt solution such as Dulbecco's phosphate buffered saline.
- the disrupting of cell membranes then includes submersing the biological tissue sample in a solution including glycerol, whereas denaturing and removing intracellular proteins includes submersing the biological tissue in at least one detergent solution.
- the one or more detergent solutions can comprise ionic detergent solutions and nonionic detergent solutions.
- the tissue sample is submersed in a succession of ionic and nonionic solutions, where the ionic detergent solutions can include sodium deoxycholate or sodium dodecyl sulfate, and the nonionic detergent solutions can include TRITON® X-100.
- the biological tissue sample is preferably rinsed with distilled water between each solution change. The resulting acellularized tissue construct can then be stored in a physiologic saline solution, and later implanted in a suitable recipient.
- FIGS. 1 a and 1 b are electron micrographs of a peripheral nerve prior to and following acellularization, respectively, according to the method of the present invention
- FIG. 2 is a toluidine blue stain of a distal end of an acellular nerve graft according to the present invention
- FIG. 4 is a light micrograph of an acellularized peripheral nerve construct according to the present invention following transplantation across a major histocompatibility barrier.
- the acellularization method of the present invention is a chemical, rather than a mechanical, process that generally involves submersion of peripheral nerve tissue in a glycerol solution followed by a series of detergents and other reagents to disrupt and digest the cellular elements of the nerve.
- the removal of cellular elements by this method does not disrupt the endoneurial matrix which is necessary to support and guide axonal regeneration. Therefore, the immunogenicity of the peripheral nerve construct of the present invention is eliminated by the removal of cellular elements, but the ability to support nerve regeneration is maintained.
- peripheral nerve tissue from any mammal, including human beings, could be similarly acellularized and grafted using the method described herein.
- 100 mm culture dishes are first prepared by mixing and pouring approximately 20 ml of SYLGARD® (Dow Coming, Midland, Mich.) into the dishes, wherein the SYLGARD® is allowed to air dry and harden for at least one week prior to use of the dishes.
- SYLGARD® Low Coming, Midland, Mich.
- rat peripheral nerve segments are then surgically removed, pinned at slack length (straight, but not taut) within the culture dishes using minutien pins, and immediately submersed in Dulbecco's Phosphate Buffered Saline (PBS) or another suitable balanced salt solution.
- PBS Dulbecco's Phosphate Buffered Saline
- the following acellularization method is carried out at room temperature ( ⁇ 21° C.) within covered culture dishes.
- the acellularization method described herein is simple, inexpensive, uses commonly available chemicals of low toxicity, and does not require mechanical agents of any kind.
- Solution 1 7.3 g EDTA 0.5 g NaN 3 800 ml Glycerol 200 ml 0.9% NaCl
- Solution 2 25 g Sodium deoxycholate (ionic detergent) 0.26 g NaN 3 600 ml distilled H 2 O
- Solution 3 10 g sodium dodecyl sulfate (SDS) (ionic detergent) 0.52 g NaN 3 1000 ml distilled H 2 O
- Solution 4 15 ml TRITON ® X-100 (nonionic detergent) 0.25 g NaN 3 485 ml distilled H 2 O Solution 5: 0.5 g NaN 3 1000 ml 0.9% NaCl
- the peripheral nerve segments are submersed with Solution 1 for approximately 72 hours in order to disrupt the cell membrane.
- the nerve segments are submersed with Solution 2 for approximately 72 hours to begin intracellular protein dissociation. Between each solution change, the nerve segments were rinsed at least once with distilled water.
- the nerve segments are again submersed with Solution 1 , this time for approximately 48 hours to complete the removal of lipid-soluble cell structures.
- the nerve segments are then submersed with Solution 3 for approximately 48 hours for additional protein denaturing.
- the nerve segments are submersed with Solution 4 for approximately 48 hours in order to remove denatured proteins from the extracellular matrix, leaving the extracellular matrix intact.
- the nerve segments are next submersed with Solution 3 for approximately 48 hours to accomplish final protein denaturing and removal.
- the nerve segments are submersed with Solution 5 where they can be stored for at least 4 weeks until use, wherein Solution 5 may be added as necessary to prevent evaporation.
- ITS intermediate toe spread
- Extensor digitorum longus (EDL) muscle contractile function was also analyzed in situ 15 weeks following the initial nerve graft surgery to determine the extent of muscle reinnervation following peripheral nerve injury and repair.
- Each rat was anesthetized, the left EDL was isolated, and the distal tendons of the EDL were divided and folded to create a tendon loop which was secured at the musculotendinous junction with 3-0 silk suture.
- the tibial and sural nerves, as well as the distal tendon of the tibialis anterior muscle were then divided to avoid motion artifact.
- the rat was placed on a platform maintained at ⁇ 37° C. by a temperature-controlled water circulator, and the EDL tendon loop was secured to the force transducer. Throughout the evaluation, muscle temperature was monitored and maintained between approximately 35° and 37° C.
- the EDL muscles were activated indirectly by delivering supramaximal electrical stimuli (square pulses, 0.2 msec pulse duration, 6-10 V) to the peroneal nerve proximal to the graft site.
- Stimuli were generated by a Grass S88 Stimulator (Grass Instrument Co., Quincy, Mass.) and delivered with a shielded bipolar silver wire electrode (Harvard Apparatus, South Natick, Mass.).
- Output from the force transducer was sampled by means of an analog-to-digital converter (Data Translation, Marlboro, Mass.) interfaced with a microcomputer. Custom software (Asyst Software Technologies, Inc., Rochester, N.Y.) was used to control data collection and to perform signal analysis.
- maximum tetanic isometric force F 0 was evaluated by stimulating the EDL muscle for 250 msec at increasing frequencies (from 30 to 350 Hz) and determining the highest force generated. Following the force measurements, the muscles were excised, the tendons trimmed, and the muscles were weighed. The results showed that at 15 weeks postoperatively the EDL muscle mass was 72.8 ⁇ 22.6 mg and F 0 was 726.3 ⁇ 608. 1 mN. Although decreased compared with values for sham-operated control animals, the recovery of force generating capabilities of EDL muscles reinnervated using acellularized nerve grafts according to the present invention assures that the regenerating axons have made functional connections with the target muscle.
- the nerve grafts were fixed in a formaldehyde/glutaraldehyde solution, then rinsed within 24 hours and transferred to storage buffer. The fixed nerves were then hydrated using graded ethanol baths prior to embedding in epoxy. Thin (10 ⁇ m) sections taken from the distal end of the nerve grafts were then mounted and stained with toluidine blue for quantitative analysis. Nerve sections also underwent electron microscopic analysis to assess nerve graft axon population as well as degree of myelination.
- FIGS. 1 a and 1 b electron micrographs of representative peripheral nerves prior to and following, respectively, the chemical acellularization method of the present invention are shown.
- FIG. 1 a depicts myelinated axons traversing the length of the nerve
- FIG. 1 b shows a lack of cellular elements and preserved endoneurial sheaths and basal lamina within the nerve.
- ECM extracellular matrix
- the acellularization method of the present invention appears to remove the Schwann cells in order to reduce the immunogenicity of the construct, but preserves the basal lamina in order to maintain the appropriate molecular signals and adhesion molecules to enhance axonal regeneration.
- the preserved basal lamina provides the appropriate adhesion molecules and molecular signals to promote Schwann cell migration, differentiation, and ultimately axonal elongation.
- a toluidine blue stained section of the distal end of a representative acellular nerve graft is shown 15 weeks after the construct was used to reconstruct a gap in a rat peroneal nerve, wherein the section was taken approximately 2 cm distal to the nerve coaptation site.
- Multiple large and small myelinated axons can be readily observed by one skilled in the art, thereby demonstrating the ability of the acellularized nerve grafts to support axonal regeneration and to allow end-organ reinnervation.
- EDL muscles were covered with cryopreservative, frozen with isopentane cooled by liquid nitrogen ( ⁇ 160° C.), and stored at ⁇ 60° C. for subsequent processing.
- Whole EDL muscle cross-sections (12 ⁇ m thick) were cut using a cryotome ( ⁇ 20° C.), then stained with hematoxylin & eosin and myosin ATPase using standard techniques for subsequent light microscopic fiber type analysis.
- acellularized nerve constructs according to the present invention were transplanted into subcutaneous pockets across a major histocompatibility barrier, from ACI rat donors to Lewis rat recipients.
- FIG. 4 a light micrograph of a section of a representative acellular nerve construct displays no evidence of an inflammatory response or any other acute or chronic rejection response.
- This preliminary experiment demonstrates that the acellularization method of the present invention produces a nerve construct that is nonimmunogenic when transplanted across major histocompatibility antigen barriers, thus immunosuppressive drugs should not be required.
- Such grafts also demonstrate axonal regeneration and successful reinnervation of the motor end organ via the nerve graft as described for the previous experiments.
- the chemically acellularized nerve constructs described herein support axonal regeneration and functional reinnervation for the reconstruction of peripheral nerve gaps.
- the chemical acellularization method according to the present invention provides a scaffold for axonal regeneration that is more suitable than that left by mechanical acellularization processes while removing all of the immunologically reactive cellular components. More particularly, the chemical acellularization method appears to preserve the delicate ultrastructure of peripheral nerves while removing the most antigenic components, namely the Schwann cells and myelin. Furthermore, the acellularization method of the present invention produces a nerve construct that induces no histologically evident acute or chronic rejection response when transplanted across major histocompatibility antigen barriers.
- Schwann cells produce many neurotrophic factors that aid in axonal regeneration, including NGF, IGF, and CNTF.
- NGF neurotrophic factor
- IGF interleukin-12
- CNTF nerve growth factor
- Additional strategies to enhance the efficacy of the acellular grafts of the present invention might include reintroducing critical growth factors into the construct through tissue culture techniques or gene derived matrices.
- the chemical acellularization method discussed herein could easily be adapted for use in clinical situations where nerve gaps are identified.
- Applications for the nerve construct and acellularization method of the present invention include peripheral nerve reconstruction after traumatic injury, reconstruction of nerve defects resulting from the resection of malignant tumors, functional reconstruction for patients with congenital syndromes where peripheral nerves are absent (e.g., Mobius Syndrome), and for the amelioration of facial paralysis and other movement disorders in some circumstances of CNS injury including strokes and spinal cord injuries. Under these circumstances, sufficient amounts of autologous nerve graft may not be present, and a nonimmunogenic, acellularized human, cadaveric allograft could be utilized for this peripheral nerve reconstruction.
- the acellularized nerve grafts could be created from donor nerves that match the recipient nerve to be reconstructed, thus the basic architecture of the nerve graft would be specific to the site of transplantation.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
- This application is a continuation-in-part of U.S. application Ser. No. 09/709, 890filed Nov. 9, 2000, which is a divisional of U.S. application Ser. No. 09/153, 721 filed Sep. 15, 1998, now U.S. Pat. No. 6,207,451.
- [0002] The invention was made with Government support under Grant No. NS34380 from the National Institute of Neurologic Disease and Stroke and Grant No. T32 AG00114 from the National Institute of Health. The Government has certain rights in this invention.
- 1. Field of the Invention
- This invention relates to the field of tissue engineering, and more particularly to a method for chemically acellularizing a biological tissue sample, such as a peripheral nerve.
- 2. Background Art
- Peripheral nerve injuries are exceedingly common, occurring clinically after injury or surgical resection. The resulting nerve gaps can produce significant disability and thus require surgical repair. Primary end-to-end nerve coaptation is the procedure of choice for peripheral nerve reconstruction, but in many circumstances the gap between the proximal and distal stump is too large to allow for a tension-free repair. Under these circumstances, surgeons must employ alternate repair techniques, such as nerve grafting.
- Peripheral nerve autografts are the gold standard for nerve grafting procedures and provide the optimal degree of reinnervation when primary end-to-end neurorrhaphy is not an option. However, the functional deficits at the donor site following nerve graft harvest as well as the limited amounts of donor nerve tissue available restrict the use of autografts in many clinical situations.
- To avoid the problems inherent in autografting, surgeons have investigated different methods of repair such as termino-lateral neurorrhaphy (TLN) and autogenous vein and plastic chamber conduits. TLN entails suturing the distal stump of a severed nerve to the side of an intact adjacent nerve which is not always available. Autogenous vein grafts and plastic chambers are a plentiful supply of nerve regeneration conduits, yet neither provides the trophic support (nerve growth factor, etc.) necessary for axonal regeneration across nerve gaps greater than 2 cm, leading to poor functional outcomes.
- Peripheral nerve allografts provide another alternative for nerve repair. Although allografts overcome the problems associated with the previously mentioned repair methods, nerve allograft rejection becomes a major obstacle. Until long term tolerance to nerve allografts can be induced, this technique requires long term systemic immunosuppression and as a result has limited clinical applications.
- Acellular nerve grafts, produced by a variety of techniques, have emerged as a possible alternative to overcome the immunogenicity of allografts. Previous attempts to create acellular nerve tissue have involved several methods, namely irradiation, fixation, heat treatment, or freezing, prior to grafting in an effort to kill or remove the cellular elements of the nerve allograft and reduce immunogenicity. Peripheral nerve grafts that have been acellularized by such methods have been shown to support axonal regeneration across short distances and to elicit a reduced immune response compared with standard peripheral nerve allografts. However, these acellularization methods cause disruption of the cellular elements of the nerve and may concurrently disrupt the endoneurial tubes, thus reducing the potential for axonal elongation through the nerve graft. In addition, cellular debris remaining after the mechanical disruption process may also elicit an immune response which can adversely affect Schwann cell migration and axonal elongation.
- Therefore, it is an object according to the present invention to provide a method for chemically acellularizing a biological tissue sample which does not rely on mechanical cell disruption.
- It is a further object according to the present invention to provide a method of acellularization which removes the cellular elements from peripheral nerve tissue while leaving the endoneurial architecture intact.
- It is another object according to the present invention to provide an acellularization method which produces an acellularized peripheral nerve construct that will support axonal regeneration across nerve gaps.
- It is still another object according to the present invention to provide an acellularization method which produces an acellularized peripheral nerve construct that is nonimmunogenic.
- Accordingly, a method is provided for chemically acellularizing a biological tissue sample, such as a peripheral nerve. The method includes disrupting the cell membranes of the biological tissue sample, and then denaturing intracellular proteins within the cells of the tissue sample and removing the denatured proteins from the cells while preserving the extracellular matrix to produce an acellularized tissue construct without using mechanical agents.
- In a preferred embodiment, the tissue sample is harvested from a suitable donor, and then submersed in a balanced salt solution, such as Dulbecco's phosphate buffered saline. The disrupting of cell membranes then includes submersing the biological tissue sample in a solution including glycerol, whereas denaturing and removing intracellular proteins includes submersing the biological tissue in at least one detergent solution. The one or more detergent solutions can comprise ionic detergent solutions and nonionic detergent solutions. Most preferably, the tissue sample is submersed in a succession of ionic and nonionic solutions, where the ionic detergent solutions can include sodium deoxycholate or sodium dodecyl sulfate, and the nonionic detergent solutions can include TRITON® X-100. In addition, the biological tissue sample is preferably rinsed with distilled water between each solution change. The resulting acellularized tissue construct can then be stored in a physiologic saline solution, and later implanted in a suitable recipient.
- The above objects and other objects, features, and advantages of the present invention are readily apparent from the following detailed description of the best mode for carrying out the invention when taken in connection with the accompanying drawings.
- FIGS. 1a and 1 b are electron micrographs of a peripheral nerve prior to and following acellularization, respectively, according to the method of the present invention;
- FIG. 2 is a toluidine blue stain of a distal end of an acellular nerve graft according to the present invention;
- FIG. 3 is a myosin ATPase stain (pH=4.3) of a rat extensor digitorum longus muscle following repair of a peroneal nerve gap with an acellularized nerve graft according to the present invention; and
- FIG. 4 is a light micrograph of an acellularized peripheral nerve construct according to the present invention following transplantation across a major histocompatibility barrier.
- A method of acellularization and the acellularized peripheral nerve construct formed thereby are described herein. The acellularization method of the present invention is a chemical, rather than a mechanical, process that generally involves submersion of peripheral nerve tissue in a glycerol solution followed by a series of detergents and other reagents to disrupt and digest the cellular elements of the nerve. As shown and described herein, the removal of cellular elements by this method does not disrupt the endoneurial matrix which is necessary to support and guide axonal regeneration. Therefore, the immunogenicity of the peripheral nerve construct of the present invention is eliminated by the removal of cellular elements, but the ability to support nerve regeneration is maintained.
- The following description and experimental results illustrate the efficacy of the chemical acellularization method of the present invention and the resulting peripheral nerve construct using nerve tissue harvested from and subsequently implanted in rats. Of course, it is fully contemplated that peripheral nerve tissue from any mammal, including human beings, could be similarly acellularized and grafted using the method described herein.
- To produce the acellular nerve constructs according to the present invention, 100 mm culture dishes are first prepared by mixing and pouring approximately 20 ml of SYLGARD® (Dow Coming, Midland, Mich.) into the dishes, wherein the SYLGARD® is allowed to air dry and harden for at least one week prior to use of the dishes. Under general anesthesia and aseptic conditions, rat peripheral nerve segments are then surgically removed, pinned at slack length (straight, but not taut) within the culture dishes using minutien pins, and immediately submersed in Dulbecco's Phosphate Buffered Saline (PBS) or another suitable balanced salt solution.
- The following acellularization method is carried out at room temperature (˜21° C.) within covered culture dishes. Advantageously, the acellularization method described herein is simple, inexpensive, uses commonly available chemicals of low toxicity, and does not require mechanical agents of any kind. Accordingly, in order to remove the cellular material, the following solutions are prepared and stored at room temperature, wherein NaN3 is used in each solution as a preservative:
Solution 1: 7.3 g EDTA 0.5 g NaN3 800 ml Glycerol 200 ml 0.9% NaCl Solution 2: 25 g Sodium deoxycholate (ionic detergent) 0.26 g NaN3 600 ml distilled H2O Solution 3: 10 g sodium dodecyl sulfate (SDS) (ionic detergent) 0.52 g NaN3 1000 ml distilled H2O Solution 4: 15 ml TRITON ® X-100 (nonionic detergent) 0.25 g NaN3 485 ml distilled H2O Solution 5: 0.5 g NaN3 1000 ml 0.9% NaCl - First, the peripheral nerve segments are submersed with
Solution 1 for approximately 72 hours in order to disrupt the cell membrane. Second, the nerve segments are submersed with Solution 2 for approximately 72 hours to begin intracellular protein dissociation. Between each solution change, the nerve segments were rinsed at least once with distilled water. Next, the nerve segments are again submersed withSolution 1, this time for approximately 48 hours to complete the removal of lipid-soluble cell structures. The nerve segments are then submersed with Solution 3 for approximately 48 hours for additional protein denaturing. Subsequently, the nerve segments are submersed with Solution 4 for approximately 48 hours in order to remove denatured proteins from the extracellular matrix, leaving the extracellular matrix intact. The nerve segments are next submersed with Solution 3 for approximately 48 hours to accomplish final protein denaturing and removal. Lastly, the nerve segments are submersed with Solution 5 where they can be stored for at least 4 weeks until use, wherein Solution 5 may be added as necessary to prevent evaporation. - Due to the technical design of the acellularization method according to the present invention, there should be no limitations on the length or diameter of nerve grafts that can be created. Larger diameter nerve grafts can be acellularized by simply employing correspondingly longer immersion times for each solution.
- Of course, it is understood that all reagent measurements and submersion times described above are approximate, and can be varied slightly without affecting the resulting acellularization. The chemical acellularization method according to the present invention was utilized in the context of acellularizing muscle tissue in commonly assigned U.S. Pat. No. 6,207,451 which is incorporated by reference herein.
- To functionally and histologically evaluate the acellularized nerve construct produced by the chemical acellularization method of the present invention, several experiments were performed. By examining the corresponding muscle force generation following nerve graft repair as well as muscle and nerve histology, microscopic structure can be correlated with functional results.
- Experiments were performed using adult male, specific-pathogen-free Fischer-344 rats (Charles River Laboratory, Kingston, N.Y.). For each animal, the left peroneal nerve was exposed and a 2 cm segment was excised to create a nerve gap and serve as a model for traumatic nerve injury. An identical length of acellularized nerve was used to repair the nerve gap. The proximal and distal ends of the peroneal nerve stumps were coapted to the proximal and distal ends of the graft in the standard end-to-end fashion using 10-0 nylon epineurial sutures. A 15 week recovery period was allowed following the initial surgery prior to measuring muscle contractile properties and analyzing muscle and nerve histology.
- Walking tracks were used to evaluate integrated motor function preoperatively and at 15 weeks postoperatively using standard protocols. Individual walking track records were digitally scanned into high-resolution computer graphic files, and measurements were performed at 2X resolution using SigmaScan Pro (Version 4.10.003, 1997, SPSS Inc.) image analysis software. For each record, 3 or 4 footprints during a period of brisk walking were used for analysis. For each footprint, the intermediate toe spread (ITS) was measured from the tip of the second toe to the tip of the fourth toe bilaterally on both the nerve grafted leg (left) and unoperated leg (right). The functional ITS index was then calculated for each walking track record using the formula ITS index=(Left ITS−Right ITS)/Right ITS. The results showed that the average ITS index value at 15 weeks following acellular nerve grafting was decreased only approximately 20% compared with the preoperative baseline value, thereby confirming at least partial recovery of integrated function using the acellular nerve grafts of the present invention.
- Extensor digitorum longus (EDL) muscle contractile function was also analyzed in situ 15 weeks following the initial nerve graft surgery to determine the extent of muscle reinnervation following peripheral nerve injury and repair. Each rat was anesthetized, the left EDL was isolated, and the distal tendons of the EDL were divided and folded to create a tendon loop which was secured at the musculotendinous junction with 3-0 silk suture. The tibial and sural nerves, as well as the distal tendon of the tibialis anterior muscle were then divided to avoid motion artifact. The rat was placed on a platform maintained at ˜37° C. by a temperature-controlled water circulator, and the EDL tendon loop was secured to the force transducer. Throughout the evaluation, muscle temperature was monitored and maintained between approximately 35° and 37° C.
- The EDL muscles were activated indirectly by delivering supramaximal electrical stimuli (square pulses, 0.2 msec pulse duration, 6-10 V) to the peroneal nerve proximal to the graft site. Stimuli were generated by a Grass S88 Stimulator (Grass Instrument Co., Quincy, Mass.) and delivered with a shielded bipolar silver wire electrode (Harvard Apparatus, South Natick, Mass.). Output from the force transducer was sampled by means of an analog-to-digital converter (Data Translation, Marlboro, Mass.) interfaced with a microcomputer. Custom software (Asyst Software Technologies, Inc., Rochester, N.Y.) was used to control data collection and to perform signal analysis. At optimal muscle length (L0), maximum tetanic isometric force (F0) was evaluated by stimulating the EDL muscle for 250 msec at increasing frequencies (from 30 to 350 Hz) and determining the highest force generated. Following the force measurements, the muscles were excised, the tendons trimmed, and the muscles were weighed. The results showed that at 15 weeks postoperatively the EDL muscle mass was 72.8±22.6 mg and F0 was 726.3±608. 1 mN. Although decreased compared with values for sham-operated control animals, the recovery of force generating capabilities of EDL muscles reinnervated using acellularized nerve grafts according to the present invention assures that the regenerating axons have made functional connections with the target muscle.
- Subsequent to the above procedures, the nerve grafts were fixed in a formaldehyde/glutaraldehyde solution, then rinsed within 24 hours and transferred to storage buffer. The fixed nerves were then hydrated using graded ethanol baths prior to embedding in epoxy. Thin (10 μm) sections taken from the distal end of the nerve grafts were then mounted and stained with toluidine blue for quantitative analysis. Nerve sections also underwent electron microscopic analysis to assess nerve graft axon population as well as degree of myelination.
- Referring now to FIGS. 1a and 1 b, electron micrographs of representative peripheral nerves prior to and following, respectively, the chemical acellularization method of the present invention are shown. As one skilled in the art will readily observe, FIG. 1a depicts myelinated axons traversing the length of the nerve, while FIG. 1b shows a lack of cellular elements and preserved endoneurial sheaths and basal lamina within the nerve. This analysis indicates that the majority of the intracellular and cell membrane components are removed by the chemical acellularization method utilized herein. The remaining material is principally extracellular matrix (ECM) which provides the structural support for nerve regeneration. Therefore, the acellularization method of the present invention appears to remove the Schwann cells in order to reduce the immunogenicity of the construct, but preserves the basal lamina in order to maintain the appropriate molecular signals and adhesion molecules to enhance axonal regeneration. Presumably, the preserved basal lamina provides the appropriate adhesion molecules and molecular signals to promote Schwann cell migration, differentiation, and ultimately axonal elongation.
- With reference to FIG. 2, a toluidine blue stained section of the distal end of a representative acellular nerve graft is shown 15 weeks after the construct was used to reconstruct a gap in a rat peroneal nerve, wherein the section was taken approximately 2 cm distal to the nerve coaptation site. Multiple large and small myelinated axons can be readily observed by one skilled in the art, thereby demonstrating the ability of the acellularized nerve grafts to support axonal regeneration and to allow end-organ reinnervation.
- Following the force measurements, the EDL muscles were covered with cryopreservative, frozen with isopentane cooled by liquid nitrogen (−160° C.), and stored at −60° C. for subsequent processing. Whole EDL muscle cross-sections (12 μm thick) were cut using a cryotome (−20° C.), then stained with hematoxylin & eosin and myosin ATPase using standard techniques for subsequent light microscopic fiber type analysis. With reference to FIG. 3, a myosin ATPase stained section (pH=4.3) of a representative EDL muscle is shown, wherein areas of large polygonal muscle fibers loosely grouped according to muscle fiber type are readily evident to those skilled in the art. Such a spatial distribution of fiber types is characteristic of reinnervated muscle.
- Therefore, the functional and histological data described above clearly demonstrate that the chemically acellularized nerve grafts of the present invention support axonal regeneration across at least a 2 cm nerve gap and that functional muscle reinnervation can be achieved.
- To evaluate immunogenicity, acellularized nerve constructs according to the present invention were transplanted into subcutaneous pockets across a major histocompatibility barrier, from ACI rat donors to Lewis rat recipients. Referring now to FIG. 4, a light micrograph of a section of a representative acellular nerve construct displays no evidence of an inflammatory response or any other acute or chronic rejection response. This preliminary experiment demonstrates that the acellularization method of the present invention produces a nerve construct that is nonimmunogenic when transplanted across major histocompatibility antigen barriers, thus immunosuppressive drugs should not be required. Such grafts also demonstrate axonal regeneration and successful reinnervation of the motor end organ via the nerve graft as described for the previous experiments.
- Therefore, the chemically acellularized nerve constructs described herein support axonal regeneration and functional reinnervation for the reconstruction of peripheral nerve gaps. The chemical acellularization method according to the present invention provides a scaffold for axonal regeneration that is more suitable than that left by mechanical acellularization processes while removing all of the immunologically reactive cellular components. More particularly, the chemical acellularization method appears to preserve the delicate ultrastructure of peripheral nerves while removing the most antigenic components, namely the Schwann cells and myelin. Furthermore, the acellularization method of the present invention produces a nerve construct that induces no histologically evident acute or chronic rejection response when transplanted across major histocompatibility antigen barriers.
- Schwann cells produce many neurotrophic factors that aid in axonal regeneration, including NGF, IGF, and CNTF. By reintroducing Schwann cells into the acellularized peripheral nerve grafts of the present invention, axonal regeneration and muscle reinnervation may be further enhanced. Additional strategies to enhance the efficacy of the acellular grafts of the present invention might include reintroducing critical growth factors into the construct through tissue culture techniques or gene derived matrices.
- The chemical acellularization method discussed herein could easily be adapted for use in clinical situations where nerve gaps are identified. Applications for the nerve construct and acellularization method of the present invention include peripheral nerve reconstruction after traumatic injury, reconstruction of nerve defects resulting from the resection of malignant tumors, functional reconstruction for patients with congenital syndromes where peripheral nerves are absent (e.g., Mobius Syndrome), and for the amelioration of facial paralysis and other movement disorders in some circumstances of CNS injury including strokes and spinal cord injuries. Under these circumstances, sufficient amounts of autologous nerve graft may not be present, and a nonimmunogenic, acellularized human, cadaveric allograft could be utilized for this peripheral nerve reconstruction. In addition, the acellularized nerve grafts could be created from donor nerves that match the recipient nerve to be reconstructed, thus the basic architecture of the nerve graft would be specific to the site of transplantation.
- While embodiments of the invention have been illustrated and described, it is not intended that these embodiments illustrate and describe all possible forms of the invention. Rather, the words used in the specification are words of description rather than limitation, and it is understood that various changes may be made without departing from the spirit and scope of the invention.
Claims (22)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/896,651 US6448076B2 (en) | 1998-09-15 | 2001-06-29 | Method for chemically acellularizing a biological tissue sample |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/153,721 US6207451B1 (en) | 1998-09-15 | 1998-09-15 | Mammalian muscle construct and method for producing same |
US09/709,890 US6777234B1 (en) | 1998-09-15 | 2000-11-09 | Mammalian muscle construct and method for producing same |
US09/896,651 US6448076B2 (en) | 1998-09-15 | 2001-06-29 | Method for chemically acellularizing a biological tissue sample |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/709,890 Continuation-In-Part US6777234B1 (en) | 1998-09-15 | 2000-11-09 | Mammalian muscle construct and method for producing same |
Publications (2)
Publication Number | Publication Date |
---|---|
US20010049138A1 true US20010049138A1 (en) | 2001-12-06 |
US6448076B2 US6448076B2 (en) | 2002-09-10 |
Family
ID=46257811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/896,651 Expired - Lifetime US6448076B2 (en) | 1998-09-15 | 2001-06-29 | Method for chemically acellularizing a biological tissue sample |
Country Status (1)
Country | Link |
---|---|
US (1) | US6448076B2 (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040067582A1 (en) * | 2000-09-12 | 2004-04-08 | Lloyd Wolfinbarger | Process for devitalizing soft-tissue engineered medical implants, and devitalized soft-tissue medical implants produced |
US20040076657A1 (en) * | 1999-06-07 | 2004-04-22 | Lifenet. | Process for decellularizing soft-tissue engineered medical implants, and decellularized soft-tissue medical implants produced |
US6743574B1 (en) | 2000-09-12 | 2004-06-01 | Lifenet | Process for devitalizing soft-tissue engineered medical implants, and devitalized soft-tissue medical implants produced |
US20040132184A1 (en) * | 1998-09-15 | 2004-07-08 | The Regents Of The University Of Michigan | System and method for forming a cardiac muscle construct |
EP1928519A1 (en) * | 2005-08-26 | 2008-06-11 | Regents of the University of Minnesota | Decellularization and recellularization of organs and tissues |
US20080241209A1 (en) * | 2007-02-02 | 2008-10-02 | The Regents Of The University Of Michigan | System and Method for Forming Bone, Ligament, and Bone-Ligament Constructs |
US20100093066A1 (en) * | 2005-08-26 | 2010-04-15 | Regents Of The University Of Minnesota | Decellularization and recellularization apparatuses and systems containing the same |
US9125971B2 (en) | 1998-06-30 | 2015-09-08 | Lifenet Health | Plasticized bone and soft tissue grafts and methods of making and using same |
US9150318B1 (en) | 2009-01-02 | 2015-10-06 | Lifecell Corporation | Method for sterilizing an acellular tissue matrix |
US9290738B2 (en) | 2012-06-13 | 2016-03-22 | Miromatrix Medical Inc. | Methods of decellularizing bone |
CN106139250A (en) * | 2016-07-29 | 2016-11-23 | 烟台正海生物科技股份有限公司 | A kind of de-cell Heterograft nerve thing and preparation method thereof |
KR20170034599A (en) | 2015-09-21 | 2017-03-29 | 이화여자대학교 산학협력단 | A method to make acellular nerve conduit for allograft |
US9744043B2 (en) | 2007-07-16 | 2017-08-29 | Lifenet Health | Crafting of cartilage |
US10233420B2 (en) | 2010-09-01 | 2019-03-19 | Regents Of The University Of Minnesota | Methods of recellularizing a tissue or organ for improved transplantability |
US11278643B2 (en) | 2016-09-06 | 2022-03-22 | Mayo Foundation For Medical Education And Research | Use of resected liver serum for whole liver-engineering |
US11452797B2 (en) | 2013-03-15 | 2022-09-27 | Miromatrix Medical Inc. | Use of perfusion decellularized liver for islet cell recellularization |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030217415A1 (en) * | 1998-06-30 | 2003-11-27 | Katrina Crouch | Plasticized bone grafts and methods of making and using same |
US7063726B2 (en) * | 1998-06-30 | 2006-06-20 | Lifenet | Plasticized bone grafts and methods of making and using same |
US7422900B1 (en) * | 1998-09-15 | 2008-09-09 | The Regents Of The University Of Michigan | System and method for forming a connective tissue construct |
US6214054B1 (en) | 1998-09-21 | 2001-04-10 | Edwards Lifesciences Corporation | Method for fixation of biological tissues having mitigated propensity for post-implantation calcification and thrombosis and bioprosthetic devices prepared thereby |
MXPA04001334A (en) * | 2001-08-13 | 2004-05-05 | Univ Florida | Materials and methods to promote repair of nerve tissue. |
US6878168B2 (en) | 2002-01-03 | 2005-04-12 | Edwards Lifesciences Corporation | Treatment of bioprosthetic tissues to mitigate post implantation calcification |
US7402319B2 (en) * | 2002-09-27 | 2008-07-22 | Board Of Regents, The University Of Texas System | Cell-free tissue replacement for tissue engineering |
US20050125049A1 (en) * | 2003-10-21 | 2005-06-09 | The Regents Of The University Of Michigan | Tissue engineered vascular construct and method for producing same |
US20060141620A1 (en) * | 2004-11-15 | 2006-06-29 | The Regents Of The University Of Michigan | System and method for forming a cardiac tissue construct |
DE102005023599A1 (en) * | 2005-05-18 | 2006-11-23 | Corlife Gbr (Vertretungsberechtigte Gesellschafter: Prof. Dr. Alex Haverich | Bioartificial heart tissue graft and process for its preparation |
WO2007056547A2 (en) * | 2005-11-08 | 2007-05-18 | Georgia Tech Research Corporation | Acellularized biomaterial from embryonic stem cells |
WO2008073582A2 (en) | 2006-10-27 | 2008-06-19 | Edwards Lifesciences Corporation | Biological tissue for surgical implantation |
US8361503B2 (en) | 2007-03-02 | 2013-01-29 | University of Pittsburgh—of the Commonwealth System of Higher Education | Extracellular matrix-derived gels and related methods |
US20080306610A1 (en) * | 2007-06-07 | 2008-12-11 | Zimmer Orthobiologics, Inc. | Tissue processing for nonimmunogenic implants |
US9101691B2 (en) | 2007-06-11 | 2015-08-11 | Edwards Lifesciences Corporation | Methods for pre-stressing and capping bioprosthetic tissue |
US8357387B2 (en) | 2007-12-21 | 2013-01-22 | Edwards Lifesciences Corporation | Capping bioprosthetic tissue to reduce calcification |
US20090292325A1 (en) | 2008-05-02 | 2009-11-26 | Cederna Paul S | Hybrid bioelectrical interface device |
US20100112696A1 (en) * | 2008-11-03 | 2010-05-06 | Baxter International Inc. | Apparatus And Methods For Processing Tissue To Release Cells |
US8309343B2 (en) | 2008-12-01 | 2012-11-13 | Baxter International Inc. | Apparatus and method for processing biological material |
US8685634B2 (en) | 2009-03-06 | 2014-04-01 | University of Pittsburgh—of the Commonwealth System of Higher Education | Neural scaffolds |
BR112012023769B1 (en) | 2010-03-23 | 2020-11-10 | Edwards Lifesciences Corporation | method for preparing bioprosthetic tissue membrane material |
US8906601B2 (en) | 2010-06-17 | 2014-12-09 | Edwardss Lifesciences Corporation | Methods for stabilizing a bioprosthetic tissue by chemical modification of antigenic carbohydrates |
US8435305B2 (en) | 2010-08-31 | 2013-05-07 | Zimmer, Inc. | Osteochondral graft delivery device and uses thereof |
US8758374B2 (en) | 2010-09-15 | 2014-06-24 | University Of Utah Research Foundation | Method for connecting nerves via a side-to-side epineurial window using artificial conduits |
US9351829B2 (en) | 2010-11-17 | 2016-05-31 | Edwards Lifesciences Corporation | Double cross-linkage process to enhance post-implantation bioprosthetic tissue durability |
US9808616B2 (en) | 2011-01-14 | 2017-11-07 | The Regents Of The University Of Michigan | Regenerative peripheral nerve interface |
WO2013066619A1 (en) | 2011-10-17 | 2013-05-10 | University Of Utah Research Foundation | Methods and devices for connecting nerves |
US10842494B2 (en) | 2011-10-17 | 2020-11-24 | University Of Utah Research Foundation | Methods and devices for connecting nerves |
US10238771B2 (en) | 2012-11-08 | 2019-03-26 | Edwards Lifesciences Corporation | Methods for treating bioprosthetic tissue using a nucleophile/electrophile in a catalytic system |
US9615922B2 (en) | 2013-09-30 | 2017-04-11 | Edwards Lifesciences Corporation | Method and apparatus for preparing a contoured biological tissue |
US10959839B2 (en) | 2013-10-08 | 2021-03-30 | Edwards Lifesciences Corporation | Method for directing cellular migration patterns on a biological tissue |
JP6681872B2 (en) | 2014-03-21 | 2020-04-15 | ユニバーシティ オブ ピッツバーグ −オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | Method for preparing final sterile hydrogel derived from extracellular matrix |
US10314725B2 (en) | 2014-11-13 | 2019-06-11 | The Regents Of The University Of Michigan | Method for amplifying signals from individual nerve fascicles |
EP4252842A3 (en) | 2017-03-02 | 2023-10-25 | University of Pittsburgh- Of the Commonwealth System of Higher Education | Ecm hydrogel for treating esophageal inflammation |
EP3589294B1 (en) | 2017-03-02 | 2022-10-26 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Extracellular matrix (ecm) hydrogel and soluble fraction thereof for use in the treatment of cancer |
EP3852683A1 (en) | 2018-11-01 | 2021-07-28 | Edwards Lifesciences Corporation | Transcatheter pulmonic regenerative valve |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3960151A (en) | 1973-11-09 | 1976-06-01 | Hemotec, Inc. | Method and means for the repair of peripheral nerves |
US4642292A (en) * | 1979-10-29 | 1987-02-10 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method for isolation of connective tissue biomatrix |
US4605623A (en) | 1982-11-08 | 1986-08-12 | Malette William Graham | Method of altering growth and development and suppressing contamination microorganisms in cell or tissue culture |
US4801299A (en) * | 1983-06-10 | 1989-01-31 | University Patents, Inc. | Body implants of extracellular matrix and means and methods of making and using such implants |
US4759764A (en) | 1985-05-24 | 1988-07-26 | Clayton Foundation For Research | Peripheral nerve regeneration |
US5266480A (en) | 1986-04-18 | 1993-11-30 | Advanced Tissue Sciences, Inc. | Three-dimensional skin culture system |
GB8618374D0 (en) | 1986-07-28 | 1986-09-03 | Hsc Res Dev Corp | Biological vascular prostheses |
US5019087A (en) | 1986-10-06 | 1991-05-28 | American Biomaterials Corporation | Nerve regeneration conduit |
US5147399A (en) | 1988-02-01 | 1992-09-15 | Dellon Arnold L | Method of treating nerve defects through use of a bioabsorbable surgical device |
US4870966A (en) | 1988-02-01 | 1989-10-03 | American Cyanamid Company | Bioabsorbable surgical device for treating nerve defects |
US4940853A (en) | 1988-07-22 | 1990-07-10 | Vandenburgh Herman H | Method for growing tissue specimens in vitro |
US5153136A (en) | 1988-07-22 | 1992-10-06 | Vandenburgh Herman H | Apparatus for growing tissue specimens in vitro |
US4963146A (en) | 1989-04-20 | 1990-10-16 | Colla-Tec Incorporated | Multi-layered, semi-permeable conduit for nerve regeneration |
US5026381A (en) | 1989-04-20 | 1991-06-25 | Colla-Tec, Incorporated | Multi-layered, semi-permeable conduit for nerve regeneration comprised of type 1 collagen, its method of manufacture and a method of nerve regeneration using said conduit |
US5521087A (en) | 1989-05-10 | 1996-05-28 | Massachusetts Institute Of Technology | Method for producing oriented connective tissue cells in a ligament configuration |
US5336616A (en) | 1990-09-12 | 1994-08-09 | Lifecell Corporation | Method for processing and preserving collagen-based tissues for transplantation |
US5840689A (en) | 1993-10-29 | 1998-11-24 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Method for stimulating the regrowth of neurons |
US5618718A (en) | 1994-12-30 | 1997-04-08 | Universite Laval | Production of a contractile smooth muscle |
US6033660A (en) | 1995-05-10 | 2000-03-07 | Genentech, Inc. | Method of treating a nervous system injury with cultured schwann cells |
US6095148A (en) | 1995-11-03 | 2000-08-01 | Children's Medical Center Corporation | Neuronal stimulation using electrically conducting polymers |
AU731768B2 (en) | 1996-09-16 | 2001-04-05 | Purdue Research Foundation | Composition and method for repairing neurological tissue |
US5925053A (en) | 1997-09-02 | 1999-07-20 | Children's Medical Center Corporation | Multi-lumen polymeric guidance channel, method for promoting nerve regeneration, and method of manufacturing a multi-lumen nerve guidance channel |
-
2001
- 2001-06-29 US US09/896,651 patent/US6448076B2/en not_active Expired - Lifetime
Cited By (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9125971B2 (en) | 1998-06-30 | 2015-09-08 | Lifenet Health | Plasticized bone and soft tissue grafts and methods of making and using same |
US9579420B2 (en) | 1998-06-30 | 2017-02-28 | Lifenet Health | Plasticized bone and soft tissue grafts and methods of making and using same |
US9585986B2 (en) | 1998-06-30 | 2017-03-07 | Lifenet Health | Plasticized bone and soft tissue grafts and methods of making and using same |
US7338798B2 (en) * | 1998-09-15 | 2008-03-04 | The Regents Of The University Of Michigan | System and method for forming a cardiac muscle construct |
US20040132184A1 (en) * | 1998-09-15 | 2004-07-08 | The Regents Of The University Of Michigan | System and method for forming a cardiac muscle construct |
US20090041729A1 (en) * | 1999-06-07 | 2009-02-12 | Lifenet Health | Process for Decellularizing Soft-Tissue Engineered Medical Implants, and Decellularized Soft-Tissue Medical Implants Produced |
US7338757B2 (en) | 1999-06-07 | 2008-03-04 | Lifenet Health | Process for decellularizing soft-tissue engineered medical implants, and decellularized soft-tissue medical implants produced |
US6734018B2 (en) | 1999-06-07 | 2004-05-11 | Lifenet | Process for decellularizing soft-tissue engineered medical implants, and decellularized soft-tissue medical implants produced |
US20040076657A1 (en) * | 1999-06-07 | 2004-04-22 | Lifenet. | Process for decellularizing soft-tissue engineered medical implants, and decellularized soft-tissue medical implants produced |
US20110143438A1 (en) * | 1999-06-07 | 2011-06-16 | Wolfinbarger Jr Lloyd | Process for Decellularizing Soft-Tissue Engineered Medical Implants, and Decellularized Soft-Tissue Medical Implants Produced |
US8574826B2 (en) | 1999-06-07 | 2013-11-05 | Lifenet Health | Process for decellularizing soft-tissue engineered medical implants, and decellularized soft-tissue medical implants produced |
US9936688B2 (en) | 2000-09-12 | 2018-04-10 | Lifenet Health | Process for devitalizing soft-tissue engineered medical implants, and devitalized soft-tissue medical implants produced |
US6743574B1 (en) | 2000-09-12 | 2004-06-01 | Lifenet | Process for devitalizing soft-tissue engineered medical implants, and devitalized soft-tissue medical implants produced |
US8563232B2 (en) | 2000-09-12 | 2013-10-22 | Lifenet Health | Process for devitalizing soft-tissue engineered medical implants, and devitalized soft-tissue medical implants produced |
US20040067582A1 (en) * | 2000-09-12 | 2004-04-08 | Lloyd Wolfinbarger | Process for devitalizing soft-tissue engineered medical implants, and devitalized soft-tissue medical implants produced |
EP1928519A4 (en) * | 2005-08-26 | 2009-07-08 | Univ Minnesota | Decellularization and recellularization of organs and tissues |
US10441609B2 (en) | 2005-08-26 | 2019-10-15 | Miromatrix Medical Inc. | Decellularization and recellularization of solid organs |
CN102861359A (en) * | 2005-08-26 | 2013-01-09 | 明尼苏达大学董事会 | Decellularization and recellularization of organs and tissues |
CN101272815B (en) * | 2005-08-26 | 2012-09-26 | 明尼苏达大学董事会 | Decellularization and recellularization of organs and tissues |
US10220056B2 (en) | 2005-08-26 | 2019-03-05 | Miromatrix Medical, Inc. | Decellularization and recellularization of solid organs |
CN102861359B (en) * | 2005-08-26 | 2015-04-01 | 明尼苏达大学董事会 | Decellularization and recellularization of organs and tissues |
US20100093066A1 (en) * | 2005-08-26 | 2010-04-15 | Regents Of The University Of Minnesota | Decellularization and recellularization apparatuses and systems containing the same |
US8470520B2 (en) | 2005-08-26 | 2013-06-25 | Regents Of The University Of Minnesota | Decellularization and recellularization of organs and tissues |
US20090202977A1 (en) * | 2005-08-26 | 2009-08-13 | Regents Of The University Of Minnesota | Decellularization and recellularization of organs and tissues |
EP1928519A1 (en) * | 2005-08-26 | 2008-06-11 | Regents of the University of Minnesota | Decellularization and recellularization of organs and tissues |
US9259510B2 (en) | 2007-02-02 | 2016-02-16 | The Regents Of The University Of Michigan | System and method for forming bone, ligament, and bone-ligament constructs |
US20080241209A1 (en) * | 2007-02-02 | 2008-10-02 | The Regents Of The University Of Michigan | System and Method for Forming Bone, Ligament, and Bone-Ligament Constructs |
US8764828B2 (en) | 2007-02-02 | 2014-07-01 | The Regents Of The University Of Michigan | System and method for forming bone, ligament, and bone-ligament constructs |
US11147674B2 (en) | 2007-07-16 | 2021-10-19 | Lifenet Health | Crafting of cartilage |
US9744043B2 (en) | 2007-07-16 | 2017-08-29 | Lifenet Health | Crafting of cartilage |
US9150318B1 (en) | 2009-01-02 | 2015-10-06 | Lifecell Corporation | Method for sterilizing an acellular tissue matrix |
US10322835B1 (en) | 2009-01-02 | 2019-06-18 | Lifecell Corporation | Method for preparing collagen-based materials |
US10906679B1 (en) | 2009-01-02 | 2021-02-02 | Lifecell Corporation | Method for preparing collagen-based materials |
US10233420B2 (en) | 2010-09-01 | 2019-03-19 | Regents Of The University Of Minnesota | Methods of recellularizing a tissue or organ for improved transplantability |
US11414644B2 (en) | 2010-09-01 | 2022-08-16 | Regents Of The University Of Minnesota | Methods of recellularizing a tissue or organ for improved transplantability |
US9290738B2 (en) | 2012-06-13 | 2016-03-22 | Miromatrix Medical Inc. | Methods of decellularizing bone |
US11452797B2 (en) | 2013-03-15 | 2022-09-27 | Miromatrix Medical Inc. | Use of perfusion decellularized liver for islet cell recellularization |
KR20170034599A (en) | 2015-09-21 | 2017-03-29 | 이화여자대학교 산학협력단 | A method to make acellular nerve conduit for allograft |
CN106139250A (en) * | 2016-07-29 | 2016-11-23 | 烟台正海生物科技股份有限公司 | A kind of de-cell Heterograft nerve thing and preparation method thereof |
US11278643B2 (en) | 2016-09-06 | 2022-03-22 | Mayo Foundation For Medical Education And Research | Use of resected liver serum for whole liver-engineering |
Also Published As
Publication number | Publication date |
---|---|
US6448076B2 (en) | 2002-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6448076B2 (en) | Method for chemically acellularizing a biological tissue sample | |
KR102167247B1 (en) | Method for decellularization of tissue grafts | |
Neubauer et al. | Chondroitinase treatment increases the effective length of acellular nerve grafts | |
Belkas et al. | Peripheral nerve regeneration through a synthetic hydrogel nerve tube | |
Cheng et al. | Urologic tissue engineering with small-intestinal submucosa: potential clinical applications | |
Tos et al. | Tissue specificity in rat peripheral nerve regeneration through combined skeletal muscle and vein conduit grafts | |
US20030040112A1 (en) | Materials and methods for nerve grafting, selection of nerve grafts, and in vitro nerve tissue culture | |
Meder et al. | Nerve-specific extracellular matrix hydrogel promotes functional regeneration following nerve gap injury | |
US20070299517A1 (en) | Articular cartilage implant | |
AU3018284A (en) | Body implants of extracellular matrix and means and methods of making and using such implants | |
Yan et al. | Use new PLGL-RGD-NGF nerve conduits for promoting peripheral nerve regeneration | |
Glasby et al. | The repair of large peripheral nerves using skeletal muscle autografts: a comparison with cable grafts in the sheep femoral nerve | |
Dornseifer et al. | Peripheral nerve reconstruction with collagen tubes filled with denatured autologous muscle tissue in the rat model | |
Ozer et al. | Regenerative potential of chitosan-coated poly-3-hydroxybutyrate conduits seeded with mesenchymal stem cells in a rat sciatic nerve injury model | |
Yokoi et al. | Bioabsorbable nerve conduits coated with induced pluripotent stem cell‐derived neurospheres enhance axonal regeneration in sciatic nerve defects in aged mice | |
US20190216977A1 (en) | Nerve treatment devices and methods | |
Potenza et al. | Evaluation of freeze-dried flexor tendon grafts in the dog | |
KOÇMAN et al. | Can a small intestine segment be an alternative biological conduit for peripheral nerve regeneration? | |
Boriani et al. | Auto-allo graft parallel juxtaposition for improved neuroregeneration in peripheral nerve reconstruction based on acellular nerve allografts | |
Deumens et al. | Limitations in transplantation of astroglia-biomatrix bridges to stimulate corticospinal axon regrowth across large spinal lesion gaps | |
Marcol et al. | Regeneration of sciatic nerves of adult rats induced by extracts from distal stumps of pre‐degenerated peripheral nerves | |
Kassar-Duchossoy et al. | Reinnervation of a denervated skeletal muscle by spinal axons regenerating through a collagen channel directly implanted into the rat spinal cord | |
Liu et al. | Experimental study of the osteogenic capacity of periosteal allografts: a preliminary report | |
Bendella et al. | Effect of surgically guided axonal regrowth into a 3-way-conduit (isogeneic trifurcated aorta) on functional recovery after facial-nerve reconstruction: Experimental study in rats | |
Kim et al. | Effectiveness and biocompatibility of decellularized nerve graft using an In vivo rat sciatic nerve model |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: REGENTS OF THE UNIVERSITY OF MICHIGAN, THE, MICHIG Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DENNIS, ROBERT G.;KUZON, WILLIAM M., JR.;CEDERNA, PAUL S.;REEL/FRAME:011956/0346;SIGNING DATES FROM 20010628 TO 20010629 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF MICHIGAN;REEL/FRAME:026000/0694 Effective date: 20110322 |
|
FPAY | Fee payment |
Year of fee payment: 12 |